Considering the established link between EMT, tumor metastasis, and poor prognosis in EGFR-mutant NSCLC, we investigated the effects of PLK1 inhibitors combined with osimertinib on the migratory properties of resistant cells. The gene discussed is PLK1; the disease is non-small cell lung carcinoma.